MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Total Assets 2011-2026 | NEOG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.44 B | 4.55 B | 4.55 B | 993 M | 920 M | 797 M | 696 M | 618 M | 528 M | 452 M | 392 M | 345 M | 291 M | 252 M | 220 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.55 B | 220 M | 1.27 B |
Quarterly Total Assets Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | 3.38 B | 3.44 B | 4.04 B | 4.05 B | 4.5 B | 4.55 B | 4.58 B | 4.6 B | 4.56 B | 4.55 B | 4.51 B | 4.56 B | 977 M | 993 M | 981 M | 968 M | 932 M | 920 M | 920 M | 846 M | 822 M | 846 M | 774 M | 751 M | 721 M | 751 M | 721 M | 660 M | 641 M | 660 M | 641 M | 581 M | 547 M | 581 M | 547 M | 487 M | 469 M | 487 M | 469 M | 426 M | 409 M | 426 M | 409 M | 366 M | 358 M | 366 M | 358 M | 320 M | 308 M | 320 M | 308 M | 270 M | 261 M | 270 M | 261 M | 234 M | 228 M | 234 M | 228 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 B | 228 M | 1.35 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 24.41 | 1.2 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 27.63 | -4.06 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Celcuity
CELC
|
245 M | $ 105.79 | 0.61 % | $ 4.17 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Danaher Corporation
DHR
|
83.5 B | $ 209.19 | - | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 11.26 | - | $ 319 M | Israel |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 23.09 | 0.35 % | $ 698 M | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 209.54 | - | $ 23.3 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 29.94 | 3.46 % | $ 832 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 19.25 | 2.45 % | $ 1.03 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 73.09 | -0.23 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
14.8 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.45 | 0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 287.13 | 0.64 % | $ 23.9 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 95.4 | 1.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 166.06 | - | $ 8.23 B | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.43 | 1.14 % | $ 410 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 104.09 | -0.54 % | $ 8.59 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 3.86 | 2.93 % | $ 2.07 M | USA |
 |
IDEXX Laboratories
IDXX
|
3.35 B | $ 649.23 | 4.19 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 122.9 | 1.96 % | $ 19.5 B | USA |
 |
Natera
NTRA
|
1.39 B | $ 209.53 | 0.09 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 164.88 | - | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 379.66 | - | $ 28.4 B |  Schweiz |
|
Biodesix
BDSX
|
97.2 M | $ 13.02 | 1.96 % | $ 1.69 B | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 21.93 | 3.49 % | $ 924 M | USA |
 |
Pacific Biosciences of California
PACB
|
1.75 B | $ 1.66 | 5.06 % | $ 421 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 31.5 | 0.9 % | $ 20 B | Niderland |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 73.61 | 0.26 % | $ 5.09 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.1 | - | $ 4.82 M | USA |